Monitoring of modified factor VIII and IX products

Haemophilia

Volumn 20, Issue S4, 2014, Pages 36-42

  Kitchen, S ^a   Gray, E ^b   Mertens, K ^c  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^c CENTRAL LABORATORY   (Netherlands)

Author keywords

Modified FIX; Modified FVIII; Monitoring

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; CHROMOGENIC SUBSTRATE; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT PROTEIN;

BLOOD CLOTTING TIME; DRUG HALF LIFE; DRUG LABELING; DRUG POTENCY; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNOGENICITY; MONITORING; PRIORITY JOURNAL; PROTEIN DETERMINATION; PUBLICATION; REVIEW; ANIMAL; BLOOD; BLOOD CLOTTING TEST; PROCEDURES; PROTEIN ENGINEERING; STANDARDS;

ANIMALS; BLOOD COAGULATION TESTS; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HUMANS; PROTEIN ENGINEERING; RECOMBINANT PROTEINS;

EID: 84899539775     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12423     Document Type: Review

References (47)

1. Brandt JT, Triplett DA, Musgrave K et al. Factor VIII assays. Assessment of variables. Arch Pathol Lab Med 1988; 112: 7-12.
2. Preston FE, Kitchen S. Quality control and factor VIII assays. Haemophilia 1998; 4: 651-3.
3. Bowyer AE, Van Veen JJ, Goodeve AC, Kitchen S, Makris M. Specific and global coagulation assays in the diagnosis of discrepant hemophilia A. Haematologica 2013; 98: 1980-7.
4. Rogers SE, Duncan EM, Sobieraj-Teague M, Lloyd JV. Evaluation of 3 automated chromogenic FVIII kits for the diagnosis of mild discrepant haemophilia A. Int J Lab Haematol 2009; 31: 180-8.
5. European Pharmacopoeia. Assay of Blood Coagulation Factor VIII (3rd edn). Strasbourg: Council of Europe, 1997. section 2.7.4; 111-4.
6. Barrowcliffe TW on behalf of the Factor VIII and IX Subcommittee of SSC of ISTH. Recommendations for the assay of high-purity FVIII concentrates. Thromb Haemost 1993; 70: 876-7.
7. Hubbard AR, Dodt J, Lee T et al. Factor VIII and Factor IX Subcommittee of the Science and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2013; 11: 988-9.
8. Lattes S, Appert-Flory A, Fischer F, Jambou D, Toulon P. Measurement of factor VIII activity using one-stage assay: a calibration curve has not to systematically included in each run. Haemophilia 2011; 17: 139-42.
9. Cauchie M, Toelen J, Peerlinck K, Jacquemin M. Practical and cost-effective measurement of B-domain deleted and full-length recombinant FVIII in the routine haemostasis laboratory. Haemophilia 2013; 19: e133-8.
10. Mackie I, Cooper PC, Lawrie A, Kitchen S, Gray E, Laffan M on behalf of British Committee for Standards in Haematology. Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. Int J Lab Haematol 2013; 35; 1-13.
11. National Committee for Clinical Laboratory Standards (USA). Determination of Factor Coagulant Activities: Approved Guideline. NCCLS, 1997. H48 -A, 17 number 4.
12. Kitchen S, McCraw A, Echenagucia M. Diagnosis of Haemophilia and Other Bleeding Disorders: A Laboratory Manual (2nd edn). Montreal, QC: World Federation of Haemophilia, 2010. Available at http://www.wfh.org. Accessed March 24, 2014.
13. Bolton-Maggs PH, Perry DJ, Chalmers EA et al. The rare coagulation disorders - review with guidelines for management. Haemophilia 2004; 10: 1-36.
14. Barrowcliffe TW, Raut S, Sands D, Hubbard AR. Coagulation and chromogenic assays of FVIII activity: general aspects standardisation and recommendations. Semin Thromb Haemost 2002; 28: 247-56.
15. Lundblad RL, Kingdom HS, Mann KG, White GC. Issues with the assay of FVIII activity in plasma and FVIII concentrates. Thromb Haemost 2000; 84: 942-8.
16. Hubbard AR, Bevan SA, Weller LJ. Potency estimation of recombinant FVIII: effect of assay method and standard. Br J Haematol 2001; 113: 533-6.
17. Lusher JM, Hillman-Wiseman C, Hurst D. In vivo recovery with products of very high purity - assay discrepancies. Haemophilia 1998; 4: 641-5.
18. Mikaelsson M, Oswaldson U, Sanderg H. Influence of phospholipids on the assessment of factor VIII activity. Haemophilia 1998; 4: 646-50.
19. Ingerslev J, Jankowski MA, Weston SB, Charles LA. Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDD Factor VIII:C activity in hemophilic plasma using the one-stage clotting assay. J Thromb Haemost 2004; 2: 623-8.
20. Pouplard C, Caron C, Aillaud MF et al. The use of the new ReFacto AF laboratory standard allows reliable measurement of FVIII:C levels in ReFacto AF mock plasma samples by a one - stage assay. Haemophilia 2011; 17: e958-62.
21. Viuff D, Barrowcliffe TW, Saugstrup T, Ezban M, Lillicrap D. International comparative field study of N8 evaluating factor VIII assay performance. Haemophilia 2011; 17: 695-702.
22. Kirkwood TB, Barrowcliffe TW. Discrepancy between one-stage and two-stage assay of factor VIII:C. Br J Haematol 1978; 40: 333-8.
23. Dawson NJ, Kemball-Cook G, Barrowcliffe TW. Assay discrepancies with highly purified factor VIII concentrates. Haemostasis 1989; 19: 131-7.
24. Hubbard AR, Weller LJ, Bevan SA. A survey of one-stage and chromogenic potencies in therapeutic factor VIII concentrates. Br J Haematol 2002; 117: 247-8.
25. Mikaelsson M, Oswalksson U, Jankowski MA. Measurement of factor VIII activity of B-domain deleted recombinant factor VIII. Semin Haematol 2001; 38: 13-23.
26. Barrowcliffe TW. Standardization of assays of factor VIII and factor IX. Ric Clin Lab 1990; 20: 155-65.
27. Hubbard AR, Weller LJ, Bevan SA. Activation profiles of factor VIII in concentrates reflect one-stage/chromogenic potency discrepancies. Br J Haematol 2002; 117: 957-60.
28. Aronson DL, Chang P. Activated factor VIII in therapeutic preparations: analysis by ultracentrifugation. Vox Sang 1996; 71: 142-9.
29. Kirkwood TB. Problems in the standardization of Factor VIII assays. Scand J Haematol Suppl 1980; 37: 110-5.
30. Raut S, Daniels S, Heath AB. Value assignment of the WHO 8th International Standard for factor VIII, concentrate (07/350). J Thromb Haemost 2012; 10: 1175-6.
31. Gray E, Pickering W, Hockley J et al. Collaborative study for the establishment of replacement batches for human coagulation factor IX concentrate reference standards. Pharmeuropa Bio 2008; 1: 19-30.
32. Available at http://www.fda.gov/biologicsbloodvaccines/bloodbloodproducts/approvedproducts/licensedproductsblas/fractionatedplasmaproducts/ucm358877.htm. Accessed March 24, 2014.
33. Available at http://www.fda.gov/biologicsbloodvaccines/bloodbloodproducts/approvedproducts/licensedproductsblas/fractionatedplasmaproducts/ucm371095.htm. Accessed March 24, 2014.
34. Leong L, Evans V, Ramsey P et al. Evaluation of methods for potency testing of pegylated FVIII (PEG-FVIII, BAY 94-9027). J Thromb Haemost 2011; 9(Suppl. 2): Poster P-TU-223.
35. Holm PK, Sorensen MH, Hermit MB, Ezban M. The Activity of GlycoPEGylated Recombinant FIX (N9-GP) can be Measured in Two-Stage Chromogenic and One-Stage Clotting Assays, 2013; PB 3.49-1, Abstract at XXIV Congress of the International Society on Thrombosis and Haemostasis. Available at http://www.eventure-online.com/eventure/publicAbstractView.do? id=217022&congressId=6839. Accessed March 24, 2014.
36. Sommer J, Yang B, Peters R, Jiang H, Gray E, Pierce GF. Comparative Field Study Evaluating the Activity of Recombinant Factor IX-Fc Fusion Protein (rFIXFc) in Plasma Samples at Clinical Haemostasis Laboratories. PB3.49-2, Abstract at XXIV Congress of the International Society on Thrombosis and Haemostasis. Available at http://www.eventure-online.com/eventure/publicAbstractView.do?id=216611&congressId=6839. Accessed March 24, 2014.
37. Lochu A, Romari N, Beltram J, Magdelaine A, Hermit MB, Ezban M. Influence of FIX and FVIII PEGylation on FIX and FVIII Activity Based on APTT Assays, 2013; PB4.54-1, Abstract at XXIV Congress of the International Society on Thrombosis and Haemostasis. Available at http://www.eventure-online.com/eventure/publicAbstractView.do?id=217440&congressId=6839. Accessed March 24, 2014.
38. Wilmot HV, Hogwood J, Gray E. The effect of different APTT reagents on the potencies of plasma-derived and recombinant factor IX concentrates in one-stage clotting assays, 2013; PB 3.49-3, Abstract at XXIV Congress of the International Society on Thrombosis and Haemostasis. Available at http://www.eventure-online.com/eventure/publicAbstractView.do?id=215891&congressId=6839. Accessed March 24, 2014.
39. Fogarty PF. Biological rationale for new drugs in the bleeding disorders pipeline. Am Soc Hematol Educ Program 2011; 2011: 397-404.
40. Pipe SW. Hemophilia: new protein therapeutics. Am Soc Hematol Educ Program 2010; 2010: 203-9.
41. Peyvandi F, Garagiola I, Seregni S. Future of coagulation factor therapy. J Thromb Haemost 2013; 11: 84-98.
42. Stennicke H, Kjalke M, Karpf DM et al. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. Blood 2013; 121: 2108-16.
43. Ostergaard H, Bjelke JR, Hansen L et al. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. Blood 2011; 118: 2333-41.
44. Metzner HJ, Weimer T, Kronthaler U, Lang W, Schulte S. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost 2009; 102: 634-44.
45. Mei B, Pan C, Jiang H, Tjandra H et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010; 116: 270-9.
46. Kulman J, Chang P-YB, Pattaroyo-White S et al. A combinatorial library approach to generate rFVIII variants with multiple XTEN insertions and improved pharmacokinetic properties. Abstract at XXIV Congress of the International Society on Thrombosis and Haemostasis, 2013. Available at http://www.eventure-online.com/eventure/publicAbstractView.do?id=216687&congressId=6839. Accessed March 24, 2014.
47. Liu T, Kulman J, Pattaroyo-White S et al. Engineering a novel rFVIII-VWF D'D3 fusion protein to enhance stability and improve pharmacokinetic properties of FVIII. Abstract at XXIV Congress of the International Society on Thrombosis and Haemostasis, 2013. Available at http://www.eventure-online.com/eventure/publicAbstractView.do?id=217527&congressId=6839. Accessed March 24, 2014.